uniQure N.V. filings document regulatory, financial, governance, and capital-structure disclosures for a Nasdaq-listed gene therapy company incorporated in the Netherlands. Form 8-K reports cover operating results, corporate updates, Regulation FD disclosures, and clinical or regulatory communications involving programs such as AMT-130 for Huntington’s disease.
Proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also includes formal disclosure categories for material agreements, financing arrangements, risk-related updates, and capital-structure matters connected to uniQure’s development-stage gene therapy portfolio.
Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 6,150,000 ordinary shares of uniQure N.V., equal to 9.87% of the company’s ordinary shares. This percentage is based on 62,291,663 shares outstanding as of November 6, 2025.
The shares were acquired solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, with Aghazadeh acting as portfolio manager and controlling person of Avoro. The filers state the holdings are in the ordinary course of business and not for changing or influencing control of uniQure.
RTW Investments, LP and Roderick Wong, M.D. report a significant ownership stake in uniQure N.V. in this amended Schedule 13G filing. They disclose beneficial ownership of 3,711,462 ordinary shares, representing 6.0% of the class, based on 62,291,663 shares outstanding as of November 6, 2025.
The shares are held by RTW-managed funds, with RTW Investments and Dr. Wong sharing voting and dispositive power over the same 3,711,462 shares. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of uniQure.
uniQure N.V. received a Schedule 13G reporting that a group of affiliated Susquehanna entities collectively beneficially owns 3,536,485 ordinary shares, or 5.7% of the company’s outstanding stock. The group includes G1 Execution Services, SIG Brokerage, Susquehanna Portfolio Strategies and Susquehanna Securities.
Their holdings include options to buy 31,000 shares at SIG Brokerage and 2,251,400 shares at Susquehanna Securities. Based on the company’s Form 10-Q, there were 62,291,663 ordinary shares outstanding as of November 6, 2025. The filing states the securities were acquired and are held in the ordinary course of business, not to change or influence control of uniQure.
State Street Corporation has disclosed beneficial ownership of uniQure common stock. It reports holding 3,231,043 shares of uniQure N.V. common stock, representing 5.2% of the class as of 12/31/2025.
State Street reports shared voting power over 3,194,147 shares and shared dispositive power over 3,231,043 shares, with no sole voting or dispositive power. The position is certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of uniQure.
uniQure N.V. (QURE) received an updated ownership report from Aberdeen Group plc and abrdn Inc. The firms report beneficial ownership of 3,678,640 ordinary shares, representing 5.91% of uniQure’s outstanding ordinary shares.
The shares are held with shared power to vote and dispose, and no sole voting or dispositive power. The reporting parties state the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of uniQure.
uniQure director Robert Gut reported option exercises and share sales in the company’s ordinary shares. On January 12, 2026, he exercised a stock option for 17,810 ordinary shares at $14.08 per share, converting derivative securities into directly held stock.
On the same date, he sold ordinary shares in several transactions: 17,310 shares at a weighted average price of $24.39 (with individual sale prices between $24.02 and $25.00), 500 shares at a weighted average price of $25.03 (with prices between $25.02 and $25.04), and 7,803 shares at $25.09. After these trades, he directly owned 32,342 ordinary shares. All transactions were carried out under a Rule 10b5-1 trading plan adopted on July 8, 2025.
uniQure N.V. filed a Form 8-K to share that it has updated its corporate presentation for investors and other stakeholders. The company is providing the new presentation as Exhibit 99.1 under a Regulation FD disclosure, meaning it is being broadly shared to keep the market informed. The presentation is also available on uniQure’s investor relations website, although the website itself and its contents are not part of this report. The company states that the information in this item and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced.
uniQure N.V. director Jack Kaye reported exercising stock options and selling shares of the company on January 9, 2026. He exercised a stock option to buy 6,390 Ordinary Shares at an exercise price of $19.39 per share, then sold the same 6,390 Ordinary Shares at a weighted average price of $27.28 per share under transaction code "S".
These trades were carried out under a pre-arranged Rule 10b5-1 sales plan adopted on June 16, 2025, as described in the footnotes. After the reported transactions, Kaye directly owned 20,439 Ordinary Shares of uniQure N.V.
uniQure has a planned sale of ordinary shares under Rule 144. A person identified as Robert Gut filed to sell 25,613 ordinary shares through Citigroup Global Markets on the NASDAQ, with an aggregate market value of $676,695.00. The filing notes that there were 62,291,663 ordinary shares outstanding at the time, providing context for the sale size.
The shares to be sold include stock acquired on January 12, 2026 through a stock option exercise and sale pursuant to a Rule 10b5-1 trading plan, as well as vested share awards originally received in 2021 and 2022 as compensation from uniQure entities. The notice also discloses that Gut sold 31,434 ordinary shares on November 6, 2025 for gross proceeds of $856,881.00, as part of the required three-month sale history.
uniQure insider plans stock sale under Rule 144
A holder of uniQure N.V. ordinary shares filed a notice of proposed sale under Rule 144 for 6,390 ordinary shares, to be handled through Citigroup Global Markets, Inc. on the NASDAQ exchange. The filing lists an aggregate market value of $174,330.00 for these shares and notes that 62,291,663 ordinary shares were outstanding. The shares are described as acquired through a stock options exercise and sale pursuant to a Rule 10b5-1 trading plan, with cash as the form of payment. The notice also reports that Jack Kaye sold 38,810 ordinary shares during the past three months for $1,177,517.00 in gross proceeds.